Aion Therapeutic Inc.
ANTCF
$0.012
-$0.003-20.00%
| 01/31/2024 | 10/31/2023 | 07/31/2023 | 04/30/2023 | 01/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 164.50K | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 164.50K | -- | -- | -- | -- |
| Cost of Revenue | 43.20K | -- | -- | -- | -- |
| Gross Profit | 121.30K | -- | -- | -- | -- |
| SG&A Expenses | 764.30K | 620.90K | 560.20K | 636.90K | 738.80K |
| Depreciation & Amortization | 11.20K | 4.40K | 8.80K | 13.10K | 14.30K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 818.60K | 625.40K | 569.00K | 650.00K | 927.70K |
| Operating Income | -654.20K | -625.40K | -569.00K | -650.00K | -927.70K |
| Income Before Tax | -1.14M | -1.02M | -979.60K | -160.40K | -904.20K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -1.14 | -1.02 | -0.98 | -0.16 | -0.90 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.14M | -1.02M | -979.60K | -160.40K | -904.20K |
| EBIT | -654.20K | -625.40K | -569.00K | -650.00K | -927.70K |
| EBITDA | -293.60K | -261.20K | -398.70K | -636.90K | -913.40K |
| EPS Basic | -0.01 | -0.01 | -0.01 | 0.00 | -0.01 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | -0.01 | -0.01 | -0.01 | 0.00 | -0.01 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 822.29M | 653.70M | 610.68M | 585.58M | 580.05M |
| Average Diluted Shares Outstanding | 822.29M | 653.70M | 610.68M | 619.99M | 614.45M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
